<code id='A49D567389'></code><style id='A49D567389'></style>
      • <acronym id='A49D567389'></acronym>
      <center id='A49D567389'><center id='A49D567389'><tfoot id='A49D567389'></tfoot></center><abbr id='A49D567389'><dir id='A49D567389'><tfoot id='A49D567389'></tfoot><noframes id='A49D567389'>
      • <optgroup id='A49D567389'><strike id='A49D567389'><sup id='A49D567389'></sup></strike><code id='A49D567389'></code></optgroup>
        5. <b id='A49D567389'><label id='A49D567389'><select id='A49D567389'><dt id='A49D567389'><span id='A49D567389'></span></dt></select></label></b><u id='A49D567389'></u>
          <i id='A49D567389'><strike id='A49D567389'><tt id='A49D567389'><pre id='A49D567389'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-10-01 16:25:00 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：entertainment   
                                        
                                      
                                      Page View：859
                                  
                                    
          
                                   
          Alastair Grant/AP
          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.
          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.
          advertisement
          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
                      
                              
          
                                 Previous article：

                                
                                          PrEP can help anyone prevent HIV. Why do so few people take it?
                                
                            
          Next article：  
                                      
                                          In age of alternative facts, a scholarly course on calling out crap
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles